74 results about "Neuronal stem cell" patented technology

The invention provides a method for modulating gene expression by contacting a cellular system with a double-stranded ribonucleic acid molecule capable of associating with a regulatory machinery that controls transcription of one or more genes, wherein the association results in altered expression of the one or more genes. The invention is further directed to method for directing the differentiation of neuronal stem cells into neurons by contacting a cellular system with a double-stranded ribonucleic acid molecule capable of associating with a regulatory machinery that controls transcription of one or more genes involved in neuronal differentiation and directing the transcription of the one or more genes. In related embodiments, the invention provides particular compositions of double-stranded ribonucleic acid molecules as well as therapeutic and screening applications of the invention.

Provided is a method of culturing a successor cell from a precursor cell comprising co-culturing a precursor cell such as, without limitation, a human embryonic stem cell or a neuronal stem cell with an adult mesenchymal stem cell. In one embodiment, the adult mesenchymal stem cell is derived from adipose tissue. Also provided is a composition comprising mesenchymal stem cells in a growth matrix biologically-compatible with the cells. In another embodiment, a method of regenerating tissue is provided comprising introducing into a patient a cell growth niche comprising either or both of mesenchymal stem cells and neuronal stem cell or successor cell in a growth matrix biologically-compatible with the cells. In another embodiment, a method of regenerating tissue is provided comprising introducing into a patient a cell growth niche comprising matrix, cells and slow release polymer beads containing growth factors.

The invention provides an inducing method for differentiating umbilical cord mesenchymal stem cells (UC-MSCs) into neural stem cells. The inducing method comprises the following steps: carrying out separation and primary culture of UC-MSCs, subculture and amplification of UC-MSCs, induction in vitro of UC-MSC to be transformed into neural stem cells, and differentiation culture of neural stem cells and detection by an immumofluorescence method. The inducing method provided by the invention uses all-transretinoic acid combined with alkaline fibroblast growth factors (bFGF) and epidermal growth factor (EGF) to induce the UC-MSCs to be transformed into neural stem cells, wherein the UC-MSCs still have stronger activity after repeated passage by division growth. The transretinoic acid is combined with cytokines to induce the UC-MSCs to be converted into the neural stem cells, so that the mesenchymal cells are differentiated into non mesenchymal cells cross germinal layer, and the mesenchymal cells probability become more ideal seed cells in the future clinical application.

Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclose describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons. The present disclosure also relates to compositions of cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons, and their precursors, that are highly enriched and can be used in variety of application. These cells can be used therapeutically to treat neurodegenerative and neuropsychiatric disorders, and can be used for disease modeling and drug screening.

This application discloses a light-responsive hydrogel-based platform that can modulate multiple microenvironmental signals to direct the differentiation of human induced pluripotent stem cell-derived neural progenitor cells (hiPSC-NPCs) into neuronal cells. The invention provides novel methods for directing differentiation of neural stem cells into neurons useful for treatment of degenerative diseases or disorders, including but not limited to Alzheimer's, Parkinson's, or spinal cord injury (SCI).

Neuregulin, a known neuroprotein, has been found to ameliorate or prevent damage caused by mechanical or chemical assault to blood vessels and, when administered into the cerebral spinal fluid, can ameliorate damage to neuronal tissue caused by stroke, inflammation or organophosphate neurotoxins. Additionally, neuregulin has been found to be useful for enhancement of stem cell migration from the ventricle to the site of injury to the brain.

An isolated expandable human neural stem or progenitor cell wherein the cell is a progenitor cells or stem cell, maintains its capability to differentiate into neurons, astrocytes, and oligodendrocytes, maintains its ability to differentiate into oligodendrocyte lineage cells efficiently throughout subsequent passages, and the cell expresses at least cell surface antigens CD133 and CD140α. Also provided is a method of in vitro culturing an expandable neural progenitor or stem cell isolated from a mammalian central nervous system, and the culture itself, wherein said cell maintains its capability to differentiate into neurons, astrocytes, and oligodendrocytes and its ability to differentiate into oligodendrocyte-lineage cells efficiently. In addition, a method of treating a condition caused by a loss of myelin or a loss of oligodendrocytes is provided as is a composition comprising an isolated expandable neural stem cell or one cultured by the methods of the invention.

The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and / or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.

The invention provides a method for modulating gene expression by contacting a cellular system with a double-stranded ribonucleic acid molecule capable of associating with a regulatory machinery that controls transcription of one or more genes, wherein the association results in altered expression of the one or more genes. The invention is further directed to method for directing the differentiation of neuronal stem cells into neurons by contacting a cellular system with a double-stranded ribonucleic acid molecule capable of associating with a regulatory machinery that controls transcription of one or more genes involved in neuronal differentiation and directing the transcription of the one or more genes. In related embodiments, the invention provides particular compositions of double-stranded ribonucleic acid molecules as well as therapeutic and screening applications of the invention.

The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and / or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.

The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.

The invention relates to a preparation method of a neural stem cell and particularly discloses a method for inducing a human mesenchymal stem cell to obtain the neutral stem cell. The method comprises the step of sequentially cultivating the mesenchymal stem cell in first, second and third culture media to obtain the neural stem cell. The finally obtained neural stem cell expresses a mark of an early neural stem cell and can be differentiated to functional neuron and neurogliocyte.

Simplified methods and compositions for directed differentiation of human pluripotent stem cells into neural stem cells are described. Methods and compositions for deriving neural stem cells from human pluripotent stem cells under defined, xeno-free conditions are also described.

The invention provides methods for obtaining neural stem cells from a mammalian embryonic or inducible pluripotent stem cell population comprising culturing mammalian embryonic or inducible pluripotent stem cells in a cell culture medium having a leukemia inhibitory factor (LIF), an inhibitor of glycogen synthase kinase 3 (GSK3), and an inhibitor of transforming growth factor β (TGF-β) under suitable conditions and obtaining isolated neural stem cells therefrom.

The invention provides methods for obtaining neural stem cells from a mammalian embryonic or inducible pluripotent stem cell population comprising culturing mammalian embryonic or inducible pluripotent stem cells in a cell culture medium having a leukemia inhibitory factor (LIF), an inhibitor of glycogen synthase kinase 3 (GSK3), and an inhibitor of transforming growth factor β (TGF-β) under suitable conditions and obtaining isolated neural stem cells therefrom.

Neuregulin, a known neuroprotein, has been found to ameliorate or prevent damage caused by mechanical or chemical assault to blood vessels and, when administered into the cerebral spinal fluid, can ameliorate damage to neuronal tissue caused by stroke or inflammation. Additionally, neuregulin has been found to be useful for enhancement of stem cell migration from the ventricle to the site of injury to the brain.

The invention provides a method for inducing neural stem cells by use of non-integrated plasmid vectors. The method comprises the steps of extraction of mononuclear cells from blood, expansion of the mononuclear cells in blood, electrotransfection of non-integrated plasmids and culture of neural stem cells. Mononuclear cells in human peripheral blood are reprogrammed into the neural stem cells which can be expanded by 60 generations or above in vitro to express related genes of the neural stem cells, nerve cells, astrocytes and oigodendrocytes can be differentiated, and the differentiated nerve cells have the electrophysiological characteristic. The method is simple to operate and extremely less in trauma.

The present invention relates to mono clonal antibodies or fragments thereof for isolating and / or identifying neural progenitor cells. The antibodies or fragments thereof bind to an identical antigen as an antibody which is produced by the hybridoma cell lines W4A5, W8C3 and 57D2 deposited on Aug. 14, 2002, at the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) under the numbers DSM ACC2571, DSM ACC2570 and DSM ACC2568.

The invention relates to the technical field of tissue engineering, in particular to a tissue engineering material for nerve injury repair as well as a preparation method and application of the tissueengineering material. The tissue engineering material for nerve injury repair is a linear ordered collagen stent of crosslinked N-cadherin. The tissue engineering material prepared by crosslinkingtheN-cadherin in the linear ordered collagen stent can efficiently induce neural stem cells to migrate towards an injury region, enrich neutral stem cells in the injury region, effectively inhibit deposition of inhibitors such as chondroitin sulfate proteolgycan and promote differentiation of the neutral stem cells towards neurons so as to promote recovery of electrophysiological and motion functions; and meanwhile, the N-cadherin crosslinked linear ordered collagen stent also has stable and ordered topological structures and excellent mechanical properties and thus can be used for repairing nerve injuries such as spinal cord injury.

The present invention relates to monoclonal antibodies or fragments thereof for isolating and / or identifying neural progenitor cells. The antibodies or fragments thereof bind to an identical antigen as an antibody which is produced by the hybridoma cell lines W4A5, W8C3 and 57D2 deposited on Aug. 14, 2002, at the under the numbers DSM ACC2571, DSM ACC2570 and DSM ACC2568.

Described herein are recombinant polynucleotide-binding polypeptides, recombinant fusion proteins made with the described polynucleotide-binding polypeptides, methods of using the described recombinant polynucleotide-binding polypeptides and recombinant fusion proteins to modify genomic DNA of cells and, in some embodiments, create recombinant cells. Methods are also provided herein for genetically modifying a neuronal stem cell. Methods are also provided for treating a neurological disorder in a subject that include the administration of genetically modified neuronal stem cells produced by the methods disclosed herein.

This application discloses a light-responsive hydrogel-based platform that can modulate multiple microenvironmental signals to direct the differentiation of human induced pluripotent stem cell-derived neural progenitor cells (hiPSC-NPCs) into neuronal cells. The invention provides novel methods for directing differentiation of neural stem cells into neurons useful for treatment of degenerative diseases or disorders, including but not limited to Alzheimer's, Parkinson's, or spinal cord injury (SCI).

Enriched neural stem and progenitor cell populations, and methods for identifying, isolating and enriching for neural stem cells using reagent that bind to cell surface markers, are provided.

The invention provides beta-(3, 4-dihydroxy benzene)-alpha-hydroxyl propionate compounds in a formula (I). The invention also relates to application of the beta-(3, 4-dihydroxy benzene)-alpha-hydroxyl propionate compounds in the formula (I) in preparing medicines for preventing A beta aggregation and / or promoting degradation of aggregated A beta, promoting proliferation of neural stem cells, and treating, preventing and / or delaying neurodegenerative diseases. The beta-(3, 4-dihydroxy benzene)-alpha-hydroxyl propionate compounds in the formula (I) can effectively treat related diseases.

The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct.

Disclosed is a composition for protecting nerve cells, promoting nerve cell growth and regenerating nerve cells comprising berberine, derivatives thereof or pharmaceutically acceptable salts thereof. The composition has protective effects against apoptosis of neuronal stem cells and differentiated neuronal stem cells, an effect of inducing the regeneration of nerve cells, a regenerative effect on neurites, a neuroregenerative effect on central nerves and peripheral nerves, a reformation effect on neuromuscular junctions, and a protective effect against apoptosis of nerve cells and a neuroregenerative effect in animals suffering from dementia and brain ischemia. Therefore, the composition can be used as a therapeutic agent for the prevention and treatment of neurodegenerative diseases, ischemic nervous diseases or nerve injuries, and for the improvement of learning capability.

The invention relates to application of astragaloside in preparation of drug for promoting neural stem cell regeneration. Research shows that astragaloside is capable of effectively promoting self-renewing and multiplication of neural stem cells, and promoting neural stem cell in mouse brain subjected to ischemia reperfusion injury to produce new neuron cells, astrocyte cells or synaptic glial cells, and the like. Therefore, the regeneration capacity of the neural stem cell can be effectively recovered.

Methods are described for the production of neurons or neuronal progenitor cells. Multipotent neural stem cells are proliferated in the presence of growth factors and erythropoietin which induces the generation of neuronal progenitor cells. The erythropoietin may be exogenously applied to the multipotent neural stem cells, or alternatively, the cells can be subjected to hypoxic insult which induces the cells to express erythropoietin.

The invention provides a method for induced transdifferentiation of somatic cells into neural stem cells, and an application of the neural stem cells, and concretely relates to neural stem cells with high yield, good pluripotency and good passage stability, formed through inducing human fibroblasts, epithelial cells, blood cells, adipocytes and other somatic cells in a normal physiological environment via a reprogramming technology by using microRNA-302, valproic acid, polybrene, epidermal growth factor and fibroblast growth factor. The method utilizes single microRNA to transfer the somatic cells without introducing an exogenous transcription factor, the clone forming time in the invention is much shorter than that in the prior art, and the neural stem cells are hopeful for developing therapeutic methods for drugs for treating degenerative neurological diseases (including spinal cord injury and other lesions), so the neural stem cells have a good clinical application prospect.